Outcomes in COVID-19 bebtelovimab studies
Outcomes in bebtelovimab studies.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 Planas . mAb use may create new variants that spread globally
Focosi . mAb use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape
Choudhary .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI]
Treatment
Control
BLAZE-4
Dougan (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Dryden-Peterson
86%
0.14 [0.01-2.76]
death
0/377
3/377
Kip
20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM)
57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Sridhara (PSM)
86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Tau2 = 0.00, I2 = 0.0%, p = 0.2
Early treatment
34%
0.66 [0.35-1.24]
15/5,868
34/7,461
34% lower risk
All studies
34%
0.66 [0.35-1.24]
15/5,868
34/7,461
34% lower risk
6 bebtelovimab COVID-19 studies
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.2
Effect extraction pre-specified (most serious outcome)
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI]
Treatment
Control
Dryden-Peterson
86%
0.14 [0.01-2.76]
0/377
3/377
Molina (PSM)
57%
0.43 [0.11-1.30]
3/3,739
11/5,423
Sridhara (PSM)
86%
0.14 [0.01-2.76]
0/1,091
3/1,091
Tau2 = 0.00, I2 = 0.0%, p = 0.078
Early treatment
60%
0.40 [0.14-1.11]
4/5,459
17/7,019
60% lower risk
All studies
60%
0.40 [0.14-1.11]
4/5,459
17/7,019
60% lower risk
4 bebtelovimab COVID-19 mortality results
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.078
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Molina
59%
0.41 [0.17-1.03]
6/3,739
21/5,423
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.056
Early treatment
59%
0.41 [0.17-1.03]
6/3,739
21/5,423
59% lower risk
All studies
59%
0.41 [0.17-1.03]
6/3,739
21/5,423
59% lower risk
1 bebtelovimab COVID-19 ICU result
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.056
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Improvement, RR [CI]
Treatment
Control
BLAZE-4
Dougan (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Dryden-Peterson
29%
0.71 [0.32-1.59]
hosp.
10/377
14/377
Molina (PSM)
56%
0.44 [0.30-0.64]
hosp.
38/3,739
107/5,423
Sridhara (PSM)
11%
0.89 [0.52-1.53]
hosp.
24/1,091
27/1,091
Tau2 = 0.08, I2 = 37.2%, p = 0.065
Early treatment
33%
0.67 [0.44-1.03]
82/5,711
152/7,147
33% lower risk
All studies
33%
0.67 [0.44-1.03]
82/5,711
152/7,147
33% lower risk
5 bebtelovimab COVID-19 hospitalization results
c19 early .org Sep 2023
Tau2 = 0.08, I2 = 37.2%, p = 0.065
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI]
Treatment
Control
BLAZE-4
Dougan (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Dryden-Peterson
86%
0.14 [0.01-2.76]
death
0/377
3/377
Kip
20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM)
57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Sridhara (PSM)
86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Tau2 = 0.00, I2 = 0.0%, p = 0.2
Early treatment
34%
0.66 [0.35-1.24]
15/5,868
34/7,461
34% lower risk
All studies
34%
0.66 [0.35-1.24]
15/5,868
34/7,461
34% lower risk
6 bebtelovimab COVID-19 serious outcomes
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.2
Effect extraction pre-specified (most serious outcome)
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Improvement, RR [CI]
Treatment
Control
BLAZE-4
Dougan (RCT)
4%
0.96 [0.95-0.97]
viral load
125 (n)
128 (n)
Tau2 = 0.05, I2 = 64.1%, p = 0.37
Early treatment
15%
0.85 [0.59-1.22]
33/377
26/256
15% lower risk
All studies
15%
0.85 [0.59-1.22]
33/377
26/256
15% lower risk
2 bebtelovimab COVID-19 viral clearance results
c19 early .org Sep 2023
Tau2 = 0.05, I2 = 64.1%, p = 0.37
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI]
Treatment
Control
BLAZE-4
Dougan (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Tau2 = 0.00, I2 = 0.0%, p = 0.62
Early treatment
-46%
1.46 [0.34-6.22]
6/504
2/256
46% higher risk
All studies
-46%
1.46 [0.34-6.22]
6/504
2/256
46% higher risk
2 bebtelovimab COVID-19 Randomized Controlled Trials
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.62
Effect extraction pre-specified (most serious outcome)
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.58
Early treatment
-151%
2.51 [0.10-61.1]
1/252
0/128
151% higher risk
All studies
-151%
2.51 [0.10-61.1]
1/252
0/128
151% higher risk
1 bebtelovimab COVID-19 RCT mortality result
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.58
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Dryden-Peterson
86%
0.14 [0.01-2.76]
death
0/377
3/377
Improvement, RR [CI]
Treatment
Control
Kip
20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM)
57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Sridhara (PSM)
86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Tau2 = 0.00, I2 = 0.0%, p = 0.091
Early treatment
46%
0.54 [0.27-1.10]
9/5,364
32/7,205
46% lower risk
All studies
46%
0.54 [0.27-1.10]
9/5,364
32/7,205
46% lower risk
4 bebtelovimab COVID-19 peer reviewed studies
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.091
Effect extraction pre-specified (most serious outcome)
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT)
-151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI]
Treatment
Control
Lilly (RCT)
-201%
3.01 [0.12-73.2]
death
1/127
0/128
Lilly (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Lilly (RCT)
-51%
1.51 [0.26-8.90]
hosp.
3/127
2/128
Lilly (RCT)
-2%
1.02 [0.15-7.16]
hosp.
2/125
2/128
Lilly (RCT)
36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Lilly (RCT)
38%
0.62 [0.35-1.10]
viral+
16/127
26/128
Lilly (RCT)
33%
0.67 [0.38-1.17]
viral+
17/125
26/128
BLAZE-4
Dougan (RCT)
-27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
BLAZE-4
Dougan (RCT)
-2%
1.02 [0.15-7.16]
hosp.
2/125
2/128
BLAZE-4
Dougan (RCT)
4%
0.96 [0.95-0.97]
viral load
125 (n)
128 (n)
BLAZE-4
Dougan (RCT)
30%
0.70 [0.63-0.78]
viral load
125 (n)
128 (n)
BLAZE-4
Dougan (RCT)
15%
0.85 [0.81-0.88]
viral load
125 (n)
128 (n)
BLAZE-4
Dougan (RCT)
39%
0.61 [0.34-1.11]
viral+
15/125
25/128
Dryden-Peterson
86%
0.14 [0.01-2.76]
death
0/377
3/377
Dryden-Peterson
43%
0.57 [0.28-1.19]
death/hosp.
10/377
17/377
Dryden-Peterson
29%
0.71 [0.32-1.59]
hosp.
10/377
14/377
Kip
20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM)
57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Molina
59%
0.41 [0.17-1.03]
ICU
6/3,739
21/5,423
Molina (PSM)
56%
0.44 [0.30-0.64]
hosp.
38/3,739
107/5,423
Molina (PSM)
46%
0.54 [0.38-0.74]
hosp.
48/3,739
116/5,423
Molina (PSM)
-33%
1.33 [1.12-1.57]
progression
260/3,739
275/5,423
Sridhara (PSM)
86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Sridhara (PSM)
25%
0.75 [0.43-1.31]
death/hosp.
24/1,091
28/1,091
Sridhara (PSM)
11%
0.89 [0.52-1.53]
hosp.
24/1,091
27/1,091
Bebtelovimab COVID-19 outcomes
c19 early .org Sep 2023
Favors bebtelovimab
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit